Blood tests included blood count, serum electrolytes, creatinine, alkaline phosphatase, glucose, amylase, and TSH tests of liver function. In addition, urine analysis and antinukle Re Antique Get body prior to the study and completed the study. Patients were evaluated by a doctor at least once a month. All adverse events were, according to the National Cancer Institute Common Terminology Criteria grading system version is rated 3, and a grant from the independent Ngigen unlikely, m Possible, probable or certain in relation to the treatment of bicalutamide or tremelimumab. Clinical response evaluation of clinical response was not the prime Re endpoint of this study. However, all subjects with CT of the abdomen and pelvis and bone scan within 4 weeks of evaluation before the first dose of bicalutamide and j Hrlichen distances Sending or as clinically indicated. Serum PSA was measured every month after starting treatment. PSA-DT was calculated using all values of serum PSA are available from Candesartan the same clinical laboratory for the period indicated and with a minimum of four PSA levels ln by the formula / b, where b is the least squares Sch Tzer The linear regression model of the PSA values in the log-transformed. Was for the pretreatment PSA DT, a period of 4 to 6 months before the treatment is used, up to and including normal day 1 of treatment. The post-treatment PSA-DT was performed using all PSA values from 6 to 12 months in the comments Ant 2 months after completion of treatment with bicalutamide, and 12 months to 18 years stay for people being treated for prostate cancer in the supervision and with other therapies. Serum immunologic assessment before treatment and at months 1, 3, 4, 5, collected, and from the study to evaluate the IgG responses. The sera were stored at 80 ° C in aliquots until use. Peripheral mononuclear
Re cells were before treatment and 5 months for the analysis of T cells collected phage immunoblot was performed to IgG responses to specific antigens we have previously described, to recognize encoded with a lambda phage 126 antigens previously considered unique to prostate cancer antigens identified in conjunction. The membranes were scanned and the digital format was visually with each positive result of independent disks Ngigen observers, blinded to Topotecan the treatment, the time of sampling layout acquisitionand membrane, assayed as described above. All membranes were labeled by the same observers at the same time. Heatmap Builder software was used to switch the display to generate heat maps antique Body immune reactions after treatment. Best Account the enzyme linked immunosorbent assay studies were conducted to evaluate IgG specific for PSA or PAP, as described above. Statistical methods of demographic variables were dose level in terms of frequencies and percentages Tze measured for categorical variables and means SD for variables on a continuous scale summary. The PSA doubling time were summarized in terms of medians and ranges. Absolute Ver Changes in the PSA-DT of pretreatment CH5424802 and post-treatment follow-up were based on a non-parametric Wilcoxon test and graphically using plots waterfall. Patient population results shown in Table 1, 11 patients were recruited for this study from September 2008.